Immunogenicity of bispecific antibodies / 中国临床药理学与治疗学
Chinese Journal of Clinical Pharmacology and Therapeutics
;
(12): 1208-1212, 2021.
Artigo
em Chinês
| WPRIM
| ID: wpr-1014966
ABSTRACT
The term bispecific antibody (bsAb) is used to describe antibodies that can recognize and bind two different antigens. Compared with the regular therapeutic antibodies, bsAbs have many advantages, such as higher sensitivity, better specificity, and are able to block multiple disease pathways simultaneously. So far, 3 bispecific antibodies have been marketed and nearly 100 are in clinical development all over the world, showing a broad development prospect. Immunogenicity of bispecific antibodies refers to the fact that the drugs will cause the immune response and produce anti-drug antibodies after entering the body, which may affect the pharmacokinetic and pharmacodynamic properties of the drugs. In this paper, the research progress on the immunogenicity of catumaxomab, blinatumomab and emicizumab was reviewed, with a view to providing reference for the safety, efficacy, and rational clinical application of bispecific antibodies.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Clinical Pharmacology and Therapeutics
Ano de publicação:
2021
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS